Document Detail


Vascular endothelial growth factor expression in early stage ovarian carcinoma.
MedLine Citation:
PMID:  9210714     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Tumor angiogenesis is essential for solid tumor growth. Yet, the importance of any particular factor in neoplastic proliferation is poorly defined. This study examines the clinical significance of increased expression of one of the angiogenic factors, vascular endothelial growth factor (VEGF), in early stage ovarian carcinoma. METHODS: Tumor specimens from 68 patients with International Federation of Gynecology and Obstetrics Stage I and II ovarian carcinoma were evaluated for VEGF expression. Antisense and corresponding sense (control) RNA probes were transcribed from the pCRII construct (Invitrogen, San Diego, CA), which contained human VEGF cDNA. The antisense probe was designed to include a highly conserved region of the VEGF coding sequence and thus detect all known variants. After in situ hybridization, sections were assessed for overexpression of VEGF. RESULTS: Twenty-nine of the tumor samples overexpressed VEGF, whereas 39 specimens did not. In patients whose tumors demonstrated elevated VEGF expression, 25% were without evidence of disease recurrence at last follow-up. In contrast, 75% of the patients whose tumors did not overexpress VEGF were without evidence of disease at last follow-up (P < 0.001). Median disease free survival for the VEGF positive group was 22 months, compared with > 108 months for the VEGF negative group (P < 0.001). When borderline tumors were excluded from the survival analysis, median disease free survival for the VEGF positive group was 18 months, compared with >120 months for the VEGF negative group (P < 0.001). Other possible prognostic variables had minimal impact on survival; these included age, stage, grade, cytology, and tumor size (P > 0.05). Assignment to a high risk group, as defined by the Gynecologic Oncology Group of the National Cancer Institute, was somewhat predictive of a shorter relapse free interval (P = 0.056). In a multivariate analysis, however, only elevated VEGF expression was associated with poorer survival. CONCLUSIONS: In this analysis, patients with early stage ovarian carcinoma with increased VEGF expression had a poorer prognosis. Further study of VEGF may ultimately lead to identification of patients with high risk lesions whose tumor biology portends a worse prognosis and who therefore may benefit from aggressive adjuvant therapy.
Authors:
P J Paley; K A Staskus; K Gebhard; D Mohanraj; L B Twiggs; L F Carson; S Ramakrishnan
Related Documents :
18161864 - Angiopoietin-1 and -2 expression in recurrent squamous cell carcinoma of the oral cavity.
17077244 - Improved survival with an intact dna mismatch repair system in endometrial cancer.
20332484 - Prognostic and predictive value of thymidylate synthase expression in primary colorecta...
1678734 - Prognostic significance of her-2/neu expression in breast cancer and its relationship t...
22833344 - A multicenter, phase ii study of epirubicin/cyclophosphamide followed by docetaxel and ...
25059344 - Clinicopathological factors predicting r0 resection and long-term survival after esopha...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer     Volume:  80     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  1997 Jul 
Date Detail:
Created Date:  1997-07-29     Completed Date:  1997-07-29     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  98-106     Citation Subset:  AIM; IM    
Affiliation:
Division of Gynecologic Oncology, University of Minnesota, Minneapolis 55455, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antisense Elements (Genetics)
Capillary Permeability
Carcinoma / pathology*
Disease-Free Survival
Endothelial Growth Factors / analysis*
Female
Humans
Logistic Models
Lymphokines / analysis*
Middle Aged
Neoplasm Staging
Neovascularization, Pathologic / pathology*
Ovarian Neoplasms / pathology*
Prognosis
RNA Probes
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
Grant Support
ID/Acronym/Agency:
CA-73871/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antisense Elements (Genetics); 0/Endothelial Growth Factors; 0/Lymphokines; 0/RNA Probes; 0/Vascular Endothelial Growth Factor A; 0/Vascular Endothelial Growth Factors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lymphoepithelioma-like carcinoma of the uterine cervix: association with Epstein-Barr virus and huma...
Next Document:  Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate...